Literature DB >> 16764346

The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers.

A Petzold1, M I Eikelenboom, G Keir, C H Polman, B M J Uitdehaag, E J Thompson, G Giovannoni.   

Abstract

This study investigated whether the new Global Multiple Sclerosis Severity Scale (MSSS) correlated with cerebrospinal fluid biomarkers for axonal and glial pathology. The MSSS correlated with the phosphorylated neurofilament heavy chain (NfH-SM135, R=0.44, P=0.016). The degree of neurofilament phosphorylation (ratio NfH-SM134 to NfH-SM135) was 8-fold higher in severely (median MSSS 6.5) versus mildly (MSSS 3.2) disabled patients (7.3 versus 0.9, P = 0.03). The MSSS may provide a statistically powerful tool for comparing overall disease severity and be useful for validating the biomarker concept in MS.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16764346     DOI： 10.1191/135248505ms1277oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  11 in total

Review 1.  Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.

Authors:  Marcelo C Pasquini; Linda M Griffith; Douglas L Arnold; Harold L Atkins; James D Bowen; Jacqueline T Chen; Mark S Freedman; George H Kraft; Gian Luigi Mancardi; Roland Martin; Paolo A Muraro; Richard A Nash; Michael K Racke; Jan Storek; Riccardo Saccardi
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-18       Impact factor: 5.742

2.  Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis.

Authors:  Fotini Pittas; Anne-Louise Ponsonby; Ingrid A F van der Mei; Bruce V Taylor; Leigh Blizzard; Patricia Groom; Obioha C Ukoumunne; Terry Dwyer
Journal:  J Neurol       Date:  2009-04-09       Impact factor: 4.849

3.  N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.

Authors:  Alessandro Trentini; Manuel Comabella; Mar Tintoré; Marleen J A Koel-Simmelink; Joep Killestein; Birthe Roos; Alex Rovira; Carsten Korth; Philipp Ottis; Marinus A Blankenstein; Xavier Montalban; Tiziana Bellini; Charlotte E Teunissen
Journal:  J Neurol       Date:  2014-09-17       Impact factor: 4.849

4.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

5.  Phosphorylated neurofilament heavy chain correlations to visual function, optical coherence tomography, and treatment.

Authors:  Joshua Pasol; William Feuer; Cui Yang; Gerry Shaw; Randy Kardon; John Guy
Journal:  Mult Scler Int       Date:  2011-03-03

Review 6.  Multiple sclerosis: integration of modeling with biology, clinical and imaging measures to provide better monitoring of disease progression and prediction of outcome.

Authors:  Shikha Jain Goodwin
Journal:  Neural Regen Res       Date:  2016-12       Impact factor: 5.135

7.  Age Related Multiple Sclerosis Severity Score: Disability ranked by age.

Authors:  Ali Manouchehrinia; Helga Westerlind; Elaine Kingwell; Feng Zhu; Robert Carruthers; Ryan Ramanujam; Maria Ban; Anna Glaser; Stephen Sawcer; Helen Tremlett; Jan Hillert
Journal:  Mult Scler       Date:  2017-02-03       Impact factor: 6.312

8.  CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome.

Authors:  M Khalil; C Enzinger; C Langkammer; S Ropele; A Mader; A Trentini; M L G Vane; M Wallner-Blazek; G Bachmaier; J-J Archelos; M J A Koel-Simmelink; M A Blankenstein; S Fuchs; F Fazekas; C E Teunissen
Journal:  Mult Scler       Date:  2012-08-23       Impact factor: 6.312

9.  Phosphorylated neurofilament heavy chain is a marker of neurodegeneration in Leber hereditary optic neuropathy (LHON).

Authors:  John Guy; Gerry Shaw; Fred N Ross-Cisneros; Peter Quiros; Solange R Salomao; Adriana Berezovsky; Valerio Carelli; William J Feuer; Alfredo A Sadun
Journal:  Mol Vis       Date:  2008-12-22       Impact factor: 2.367

Review 10.  Promoting remyelination in multiple sclerosis-recent advances.

Authors:  E Jolanda Münzel; E Jolanda Münzel; Anna Williams
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.